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Abstract
Identiﬁcation of a systemically acting and universal small molecule therapy for Duchenne muscular dystrophy would be an
enormous advance for this condition. Based on evidence gained from studies on mouse genetic models, we have identiﬁed
tyrosine phosphorylation and degradation of β-dystroglycan as a key event in the aetiology of Duchenne muscular dystrophy.
Thus, preventing tyrosine phosphorylation and degradation of β-dystroglycan presents itself as a potential therapeutic strategy.
Using the dystrophic sapje zebraﬁsh, we have investigated the use of tyrosine kinase and other inhibitors to treat the dystrophic
symptoms in this model of Duchenne muscular dystrophy. Dasatinib, a potent and speciﬁc Src tyrosine kinase inhibitor,
was found to decrease the levels of β-dystroglycan phosphorylation on tyrosine and to increase the relative levels of non-
phosphorylated β-dystroglycan in sapje zebraﬁsh. Furthermore, dasatinib treatment resulted in the improved physical
appearance of the sapje zebraﬁsh musculature and increased swimming ability as measured by both duration and distance of
swimming of dasatinib-treated ﬁsh compared with control animals. These data suggest great promise for pharmacological
agents that prevent the phosphorylation of β-dystroglycan on tyrosine and subsequent steps in the degradation pathway as
therapeutic targets for the treatment of Duchenne muscular dystrophy.
Introduction
The zebraﬁshDanio reriohas rapidly been adopted as an organism
of choice for all aspects of the drug discovery pipeline (1–3). The
zebraﬁsh system offers unique advantages for drug screening in
a vertebrate model organism, and in particular, muscular dys-
trophies are especially amenable due to their early, robust and
readily recognizable phenotypes (4,5). The small size, embryon-
ic status, low cost and ease of drug delivery directly via the
water, makes zebraﬁsh a very attractivemodel for whole-organ-
ism screening. Zebraﬁsh show a typical vertebrate development
pattern, and in the mutants, perturbation of muscle architec-
ture and muscle function is readily observable even in the
embryonic stages (4–6). In addition, of the genes known to be
mutated in human forms of muscular dystrophy, many are re-
presented in the zebraﬁsh genome and those investigated so
far exhibit dystrophic phenotypes in zebraﬁsh (7,8). Although
candidate compounds identiﬁed in ﬁsh would need to be vali-
dated in mammals before being taken on to human therapy,
the low cost and speed of candidate drug screening, far out-
weigh any disadvantages.
Recent unbiased screens for DMD therapeutics have also vali-
dated this approach and identiﬁed a number of compounds that
appear effective in reducing dystrophic symptoms in zebraﬁsh
(9,10). In particular, the identiﬁcation of PDE5 inhibitors appears
to be useful in this regard as they have also been shown to be
effective in mdx mice (11,12).
Previous studies from the Lisanti group and ourselves
suggested that tyrosine phosphorylation of dystroglycan is an
important mechanism for controlling the association of dystrogly-
can with its cellular binding partners, dystrophin and utrophin,
and also as a signal for degradation of dystroglycan (13–15). The
Lisanti group further demonstrated that inhibition of the
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proteasome was able to restore other dystrophin glycoprotein
complex (DGC) components in bothmdxmice that lack dystroph-
in and in explants of DMD patients (16,17). As a ﬁrst step, we ex-
amined the proteasomal inhibitor MG132 as a proof of principle
in the zebraﬁsh system comparing wild-type with dystrophic
sapje larvae. As has been demonstrated for MG132 in mice and
patient explants (16,17), we found that MG132 was also effective
in sapje zebraﬁsh in reducing the dystrophic phenotype (18).
Moreover, in a genetic mouse model containing a tyrosine to
phenylalaninemutation at residue 890 (Y890F) in β-dystroglycan,
we demonstrated that preventing tyrosine phosphorylation of
β-dystroglycan in mdx mouse alleviated the dystrophic pheno-
type (19). Taken together, these studies suggest a pathway in
DMD where loss of dystrophin leads to increased phosphoryl-
ation of β-dystroglycan on tyrosine. This in turn results in the
internalization and degradation of β-dystroglycan via the prote-
asome, leading to the loss of the entire DGC from the sarcolemma
with an ensuing dystrophic phenotype. This pathway presents,
therefore, three clear druggable targets through which to effect
a treatment: inhibition of tyrosine phosphorylation of β-dystro-
glycan, inhibition of the ubiquitination of β-dystroglycan, and in-
hibition of the proteasomal degradation of β-dystroglycan. We
have therefore tested candidate compounds with the relevant
biological activities for their ability to reduce the dystrophic
phenotype in sapje zebraﬁsh and identiﬁed dasatinib as a poten-
tial therapeutic that could be repurposed to treat DMD.
Results
Homozygous sapje zebraﬁsh show a progressive loss of muscle
organization visible from 3 days post-fertilization (dpf) onwards
(6,20). Concomitant with the loss of muscle organization, as
observed by birefringence or ﬂuorescence in whole embryos, is
a progressive loss of immunoreactivity from the myosepta of
other DGC components such as dystroglycan, comparedwith sib-
lings (Supplementary Material, Fig. S1). The loss of other DGC
components in the absence of dystrophin is common with
other models of Duchenne muscular dystrophy (DMD) such
as the mdx mouse (21), and in people with DMD (22). In order to
more reliably quantify the extent of dystroglycan loss in sapje
embryos, we performed quantitative western blotting of sapje
and sibling larvae at 3, 4 and 5 dpf and examined the levels of
β-dystroglycan, and β-dystroglycan phosphorylated on tyrosine,
normalized to tubulin levels. As can be seen in Figure 1A, and
in keeping with the immunoﬂuorescence (IF) results in Supple-
mentaryMaterial, Figure S1, there is a progressive and signiﬁcant
loss of β-dystroglycan from 3 to 5 days in sapje larvae relative to
siblings. In contrast to non-phosphorylated dystroglycan, tyro-
sine-phosphorylated β-dystroglycan does not decline until Day
5 (Fig. 1B and C). Therefore, there is a loss of non-phosphorylated
β-dystroglycan that may contribute initially to the levels of
tyrosine phosphorylated β-dystroglycan, but by 5 dpf, both non-
phosphorylated and phosphorylated dystroglycan are signiﬁ-
cantly reduced. Also noticeable in Figure 1A, upper panels, is
the appearance of higher molecular weight bands of tyrosine
phosphorylated β-dystroglycan with a mass of ∼53 and 63 kDa,
equivalent to 10 or 20 kDa heavier than the main 43 kDa
β-dystroglycan band. Thus, the absence of dystrophin in sapje
ﬁsh leads to a decrease in 43 kDa β-dystroglycan, with the
concomitant appearance of slower migrating phosphorylated
β-dystroglycan species. These data suggest a mechanism where-
by in the absence of dystrophin, β-dystroglycan is more prone to
phosphorylation on tyrosine; this results in a relative decrease in
un-phosphorylated β-dystroglycan levels, and a concomitant
increase in tyrosine-phosphorylated β-dystroglycan levels. This
in turn leads to ubiquitin-mediated proteasomal degradation
and a reduction in levels of all forms of dystroglycan by 5 dpf.
The higher molecular weight dystroglycan bands may therefore
represent ubiquitinated species. Assuming this is the case, the
10 and 20 kDa higher forms might represent the addition of one
or two ubiquitin moieties.
We have previously used H2kb-tsA58 myoblasts to follow the
fate of β-dystroglycan following tyrosine phosphorylation and in-
ternalization (19). Using a surface biotinylation and pulse chase
approach, we were able to demonstrate that at 20 min following
onset of endocytosis/labelling we were able to detect exclusively
tyrosine phosphorylated β-dystroglycan in the internalized pellet
fraction, whereas no internalized non-phosphorylated β-dystro-
glycan was detectable (Fig. 2A and B). Furthermore, the presence
of twohighermolecularweight bandswas also evident, but again
only in the internalized tyrosine-phosphorylated β-dystroglycan
fraction (Fig. 2B). To identify the higher molecular weight,
tyrosine phosphorylated β-dystroglycan bands, myoblast lysates
were subject to pull-down with glutathione-S-transferase (GST)-
MultiDsk (23) a protein comprising three repeated ubiquitin-
binding domains fused to GST. As can be seen from Figure 2C, a
higher molecular weight band was pulled down by the MultiDsk
protein, but was only recognized by the antibody raised against
tyrosine-phosphorylated β-dystroglycan and not by the antibody
Figure 1. Levels of β-dystroglycan and β-dystroglycan phosphorylated on tyrosine
in sapje and sibling larvae. Western blots of lysates of individual 3, 4 and 5 dpf
sibling and sapje larvae western blotted with antibodies against phosphorylated
β-dystroglycan [p-β-DG, (A) top], non-phosphorylated β-dystroglycan [β-DG, (A)
middle] and α-tubulin was used as a loading control [α-tub, (A) bottom]. Numbers
represent relative position of molecular weight markers in kDa. (B and C) The
integrated density of the blots probed against β-DG and p-β-DG shown in (A),
quantiﬁed relative to α-tubulin levels in each sample. Graphs show mean + SEM
of 12 (B) or 9 (C) samples from three independent experiments in each case.
(B) There is a signiﬁcant decrease in the level of β-dystroglycan in larvae with the
sapjemutation at 3, 4 and 5 dpf (unpaired t-tests, 3 dpf: P = 0.0016; 4 dpf: P<0.0001;
5 dpf P < 0.0001). (C) Levels of phosphorylated dystroglycan are slightly increased
in sapje at 3 and 4 dpf, but this increase is not statistically signiﬁcant (P > 0.05).
When compared with sibling lysates, levels of phosphorylated dystroglycan at
5 dpf are signiﬁcantly lower in sapje (P = 0.0007).
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that detects unphosphorylated dystroglycan. These data suggest
that internalized tyrosine phosphorylated β-dystroglycan is also
ubiquitinated, and thus provides an explanation for the higher
molecular weight bands in Figure 2B and as seen in whole zebra-
ﬁsh muscle in Figure 1A. Further conﬁrmation of the ubiquitina-
tion of tyrosine phosphorylated β-dystroglycanwas also provided
by the reciprocal detection of higher molecular bands with an
antibody raised against ubiquitin following pull-down of tyrosine
phosphorylated β-dystroglycan (Fig. 2C).
Taken together, the data in Figures 1 and 2 further sub-
stantiate a mechanism whereby in the absence of dystrophin,
β-dystroglycan is phosphorylated on tyrosine, internalized and
ubiquitinated, then degraded (Fig. 3). Based on this pathway, we
undertook a candidate-based approach in zebraﬁsh to identify
compounds or drugs that could inhibit this pathway at different
points, and that could therefore potentially alleviate the dys-
trophic symptoms by preventing dystroglycan phosphorylation
and degradation. We have demonstrated previously in a mouse
genetic model, that preventing tyrosine phosphorylation of
β-dystroglycan ameliorates the mdx dystrophic phenotype (19).
As the in vitro and in vivo data suggest that Src-mediated tyrosine
phosphorylation of β-dystroglycan is the initial step in the de-
gradative cascade, we sought to determine using small molecule
inhibitors of Src, whether in vivo in ﬁsh there was any effect of
dystroglycan phosphorylation on tyrosine in the dystrophic
phenotype. Using the selective Src kinase inhibitor dasatinib
(24), we examined whether dasatinib affected the levels of tyro-
sine phosphorylated β-dystroglycan in London wild-type (LWT)
zebraﬁsh embryos. As can be seen in Figure 4, compared with di-
methyl sulfoxide (DMSO) vehicle alone, dasatinib at 1 and 5 µ
caused a signiﬁcant reduction in the levels of tyrosine phos-
phorylated β-dystroglycan, with a corresponding increase in le-
vels of non-phosphorylated β-dystroglycan. Furthermore, at all
concentrations of dasatinib tested between 0.5 and 5 µ there
was a signiﬁcant reduction in the ratio of phosphorylated to
non-phosphorylated β-dystroglycan.
Having established that dasatinib treatment of normal zebra-
ﬁsh could alter the extent of dystroglycan phosphorylation, we
next examined the effect of dasatinib in sapje zebraﬁsh. As was
seen in the LWT zebraﬁsh, dasatinib at 1 and 5 µ caused a
signiﬁcant anddose-dependent decrease in β-dystroglycan phos-
phorylation, with a concomitant increase in the levels of
non-phosphorylated β-dystroglycan (Fig. 5). Based on the scheme
presented in Figure 3, the ultimate fate of phosphorylated dystro-
glycan is proteasomal degradation. We, therefore, investigated
Figure 2. Phosphorylation and ubiquitination of β-dystroglycan in H2K
myoblasts. Western blots for tyrosine-phosphorylated β-dystroglycan (p-β-
DG, upper panels) or non-phosphorylated β-dystroglycan (β-DG, middle
panels) from a pulse-chase surface biotinylation assay (19) at time 0 (A) and
after 20 min of internalization (B). No dystroglycan is internalized to the pellet
fraction at time 0 (A), whereas only tyrosine phosphorylated β-dystroglycan is
recovered in the internalized pellet fraction at 20 min (B). Furthermore, note
the appearance of higher molecular weight bands of tyrosine phosphorylated
β-dystroglycan in the internalized fraction in (B). α-Tubulin (α-tub) and an
unknown concanavalin A (Con A)-binding protein are used as loading controls
for the supernatant (surface membrane fraction) and pellet (internalized fraction),
respectively. (C) Supernatant (S) and pellet (P) samples from control GST and
GST-MultiDsk pull-down were separated by SDS–PAGE and western blotted for
pY890 β-dystroglycan [p-β-DG, (C) lower panel] or the unphosphorylated counterpart
[β-DG, (C) upper panel]. Only tyrosine phosphorylated β-dystroglycan was pulled
down by the MultiDsk ubiquitin binding protein. Immunoprecipitation from H2K
myoblasts using p-β-dystroglycan antibody were western blotted probed for
ubiquitin [Ubi, (D) upper panel] and phosphorylated β-DG [p-βDG, (D) lower
panel]. Arrowheads in (D) indicate altered forms of p-β-dystroglycan, whereas the
asterisk indicates non-speciﬁc immunoreactivity due to cross-reaction of rabbit
IgG chains between the IP and blot. Numbers represent relative position of
molecular weight markers in kDa.
Figure 3.A schematic of the fate of internalized β-dystroglycan. β-DG is shownas a
lollipop shape, inserted in membrane (represented by a line) with cytoplasmic
domain directed down and the WW domain binding motif/Src tyrosine
phosphorylation site PPPYVPP shown. Arrows show the sequence of events,
with 1. Tyrosine phosphorylation by Src at Y890 (pY in circle) followed by
2. Endocytosis into a vesicle followed by 3. Ubiquitination (Ubi in octagon) and
ultimately 4. Proteasomal degradation. T-shaped bars on the right indicate
stages of the process that could be inhibited pharmacologically.
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the effect of the proteasome inhibitor MG132 (25) on the levels of
dystroglycan and phosphorylated dystroglycan in sapje zebraﬁsh.
As can be seen in Figure 6, MG132, like dasatinib, also increased
the levels of both β-dystroglycan and phosphorylated β-dystro-
glycan, suggesting that blocking proteasomal degradation re-
duces the break-down of phosphorylated β-dystroglycan which
accumulates in themuscle and further leads to increase in the le-
vels of non-phosphorylated β-dystroglycan which is beneﬁcial to
the sapje ﬁsh. Quantitatively similar data were also obtained for
the ubiquitin ligase inhibitor Pyr41 (26) (Supplementary Material,
Fig. S2), where inhibition of the intermediate stages of the
proposed pathway (outlined in Fig. 3) also resulted in a signiﬁcant
increase in the levels of both phosphorylated β-dystroglycan and
non-phosphorylated β-dystroglycan. Therefore, inhibition of the
tyrosine kinase resulted in an increase in the non-phosphory-
lated form of β-dystroglycan, and inhibition of the ubiquitin-pro-
teasome pathway resulted in an increase in the levels of both the
non-phosphorylated and phosphorylated β-dystroglycan. This is
likely to be due to the phosphorylated dystroglycan not being de-
graded, which consequently leads to an increase in levels of non-
phosphorylated dystroglycan. Furthermore, treatment of sapje
ﬁsh with dasatinib from 24 to 72 hpf resulted in a signiﬁcant
and dose-dependent reduction in the proportion of embryos
with a dystrophic phenotype (Fig. 7). The effect of dasatinib plat-
eaued at ∼2 µ, with an estimated 40% of the dystrophic popula-
tion displaying a normal muscle birefringence. When assessing
the severity of the birefringence phenotype, there appeared to
be a marked decrease in the percentage of ﬁsh showing a severe
phenotype (Fig. 7A). While these data indicate that dasatinib can
reduce the levels of dystroglycan phosphorylation, which from
the mouse model (19) would be predicted to be beneﬁcial, and
produces an improvement in the integrity of the muscle as mea-
sured by birefringence (18), we alsowanted to determinewhether
drug treatment had resulted in any improvement inmuscle func-
tion. To test muscle function in the zebraﬁsh embryos we used a
high-speed video-tracking system to measure the swimming
Figure 5. The effect of dasatinib treatment on levels of phosphorylated and non-
phosphorylated β-dystroglycan in sapje zebraﬁsh larvae. Lysates were made from
sapje–/– embryos treated from 24 hpf until 96 hpf with dasatinib or DMSO-only.
(A) Western blots probed with antibodies for p-β-DG and α-tubulin. (B) The
density of the blot probed for p-β-DG was quantiﬁed relative to α-tubulin levels in
each sample, and normalized to the average control signal. There is a signiﬁcant
decrease in the level of phosphorylated β-dystroglycan in larvae treated with
dasatinib, compared with controls. (C) Western blots probed with antibodies for
β-DG and α-tubulin. Numbers in (A and C) represent relative position of
molecular weight markers in kDa. (D) The density of the blot probed against
β-DG was quantiﬁed relative to α-tubulin levels in each sample, and normalized
to the average control signal. There was a signiﬁcant difference in the levels of
β-DG in larvae between different treatment groups. Graphs show mean + SEM of
at least six samples for each treatment, from three independent experiments.
One-way ANOVA was carried out followed by Dunnett’s multiple comparison
test (ns, non-signiﬁcant; ***P < 0.001).
Figure 4. Phosphorylated β-dystroglycan in dasatinib-treatedwild-type zebraﬁsh
larvae. Pools of 10 LWT zebraﬁsh embryos were treated with dasatinib or DMSO
from 24 hpf until 96 hpf and then lysed for SDS–PAGE. (A) A western blot of
lysates probed with antibodies against phosphorylated β-dystroglycan (top
panel), β-dystroglycan (middle panel) and α-tubulin (bottom panel). Numbers
represent relative position of molecular weight markers in kDa. (B) The
density of the blot probed against phosphorylated dystroglycan was quantiﬁed
relative to α-tubulin levels in each sample, and represented as a ratio to the
average DMSO only control signal. There is a signiﬁcant decrease in the level
of phosphorylated β-dystroglycan in dasatinib-treated embryos, compared
with DMSO-treated controls. (C) The density of the blot probed against
phosphorylated dystroglycan was quantiﬁed relative to non-phosphorylated
dystroglycan levels in each sample, and normalized to the average DMSO only
control signal. There is a signiﬁcant decrease in the ratio of phosphorylated to
non-phosphorylated dystroglycan in dasatinib-treated embryos, compared
with DMSO-treated controls. Graphs show mean + SEM of at least eight
samples for each treatment, from three independent experiments. One-way
analysis of variance (ANOVA) was carried out followed by Dunnett’s multiple
comparison test (ns, non-signiﬁcant; ***P < 0.001).
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activity of individual ﬁsh over a 10 min period. When compared
with normal siblings, it is immediately apparent from the tracks
of sapje ﬁsh compared with normal siblings, that they are consid-
erably poorer at swimming (Fig. 8A and B). Evenwhen stimulated
with convulsants such as pentylenetetrazole (27), sapje swim-
ming ability was not increased (data not shown). All recorded
measures of swimming activity were signiﬁcantly lower in sapje
ﬁsh including total time spent swimming, time spent swimming
at fast or slow speeds and time spent swimming for short or long
distances (data not shown), and total distance swum in 10 min
(Fig. 8A). Dasatinib treatment of sapje ﬁsh between 3 and 5 dpf re-
sulted in a signiﬁcant increase in total distance swum in 10 min
(Fig. 8C), indicating that the drug treatment not only has a bio-
chemical and a histological effect, but also a physiological effect
in increasing swimming activity in this ﬁsh model of DMD. Even
at concentrations as high as 10 µ, however, dasatinib treatment
had no effect on the birefringence phenotype of another dys-
trophic zebraﬁsh model: the dystroglycan null zebraﬁsh (Supple-
mentary Material, Fig. S3). This strengthens the notion that the
mechanism by which dasatinib treatment is able to improve
muscle integrity is dependent on dystroglycan expression and
its phosphorylation in the absence of dystrophin, as no improve-
ment was seen in a dystrophic ﬁsh that lacks dystroglycan (Sup-
plementary Material, Fig. S3).
Discussion
The phosphorylation of β-dystroglycan on tyrosine acts as a
molecular switch to regulate its interactions between different
potential binding partners and different cellular adhesion func-
tions (28). Phosphorylation of β-dystroglycan also acts as a switch
to determine its intracellular fates, including internalization by
endocytosis (15,19), trafﬁcking to the nucleus (29–31) and, as we
demonstrate here, proteasomal degradation. Dystroglycan phos-
phorylation was originally identiﬁed as a signal downstream of
laminin engagement that led to regulation via alterations in the
interactions between dystroglycan and several cytoskeletal li-
gands (14). The number of potential interactions and the degree
of complexity of tyrosine phosphorylation regulated associations
of dystroglycan have grown considerably in the last 10 years (28).
Furthermore, with the identiﬁcation of the kinase responsible—
Src (32), the precise phosphorylation site (14,32), and with anti-
bodies to distinguish the phosphorylated epitope, it has become
clearer that tyrosine phosphorylation of dystroglycan is not sim-
ply a switch to modulate different binding partners during cell
adhesion and migration, but also serves as a switch to control
the internalization and intracellular trafﬁcking of dystroglycan
(15,19,33). Furthermore, tyrosine phosphorylation of dystrogly-
can serves as a speciﬁc signal for the endocytic uptake and
Figure 7. The effect of 72 h dasatinib treatment on sapje muscle phenotype.
Embryos were treated with dasatinib or DMSO only for 72 h before a
birefringence assay was carried out. The number of larvae showing normal or
disrupted muscle birefringence was counted. (A) The proportion of larvae
showing mild, moderate and severe muscle damage. There was a signiﬁcant
decrease in the percentage of larvae showing a severe phenotype in the groups
treated with dasatinib compared with DMSO alone. (B) The overall percentage
rescue of the dystrophic phenotype is plotted against dasatinib concentration.
Data are plotted taking the proportion of dystrophic ﬁsh in DMSO-only treated
groups as 0% rescue (one-way ANOVA followed by Dunnett’s multiple
comparison test: *P < 0.05, **P < 0.01 and ***P < 0.001). Data points represent mean
values of ﬁve independent experiments, with a total of ∼250 embryos per
treatment group. Error bars represent SEM.
Figure 6. The effect of MG132 treatment on levels of phosphorylated and non-
phosphorylated β-dystroglycan in sapje zebraﬁsh larvae. Lysates were made
from sapje−/− embryos treated from 24 hpf until 96 hpf with 5 μ MG132 or
DMSO-only. (A) Western blots probed with antibodies for β-dystroglycan (β-DG)
and α-tubulin (α-tub). (B) The density of the blot probed with β-DG was
quantiﬁed relative to α-tubulin levels in each sample, and normalized to the
average control signal. There was a signiﬁcant increase in the level of
β-dystroglycan in larvae treated with MG132, compared with controls
(unpaired t-test: t = 4.048, df = 10, P = 0.0023). (C) Western blots probed with
antibodies for phosphorylated β-dystroglycan (p-β-DG) and α-tubulin. (D) The
density of the blot probed with p-β-DG was quantiﬁed relative to α-tubulin
levels in each sample, and normalized to the average control signal. There
was a signiﬁcant increase in the levels of β-DG in larvae between different
treatment groups (unpaired t-test: t = 11.47, df = 10, P < 0.0001). Graphs
represent the mean of six samples from three independent experiments,
error bars are SEM.
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proteasomal degradation of dystroglycan (19). We and others
have hypothesized that this signalling event contributes to the
aetiologyof DMDdue to its effect on the proteasomal degradation
of not only dystroglycan itself, but also other components of the
sarcolemmal DGC. Furthermore, Src kinase expression is ele-
vated in mdx, the mouse model of DMD (34). As these analyses
have revealed, tyrosine phosphorylation of dystroglycan appears
to target the protein for endocytosis, resulting in ubiquitination
leading to proteasomal degradation. This apparent pathway
thus provides several points of potential therapeutic interven-
tion, including inhibition of tyrosine kinases, preventing ubiqui-
tination and blocking proteasomal activity. As previous analyses
in zebraﬁsh, mice, dogs and patient explants have shown, block-
ing degradative pathways pharmacologically with MG132 or bor-
tezomib (Velcade) is able to restore components of the DGC to the
sarcolemma, and has a beneﬁcial effect on the dystrophic pheno-
type (16–18,35–37). However, one report of longer term treatment
with the proteasome inhibitor MG132 failed to show any beneﬁt
(38). Bortezomib has also been demonstrated recently to beneﬁt
the dystrophic symptoms of the dy/dy mouse, a model of con-
genital muscular dystrophy MDC1A (39). Indeed, preventing
phosphorylation and degradation of dystroglycan may be of
beneﬁt in other muscular dystrophies. For example, hypoglyco-
sylation of dystroglycan in FKRP-deﬁcient zebraﬁsh invokes an
unfolded protein response (UPR) (40) and increased degradation
of dystroglycan. However, the role of tyrosine phosphorylation
of dystroglycan in the UPR and subsequent degradation steps is
still to be determined.
In our efforts to further dissect the signalling pathways re-
sponsible for DMD, and following the success of blocking phos-
phorylation of tyrosine 890 in dystroglycan in a mouse genetic
model (19), we examined the effect of blocking tyrosine kinases
on the zebraﬁsh dystrophic phenotype. The Lisanti group had
identiﬁed Src as the tyrosine kinase responsible for phosphoryl-
ation of dystroglycan at Y890 in a number of in vitro and cell cul-
ture assays (15,32). In our efforts to expedite the drug discovery
pipeline for DMD, we therefore decided to examine Src inhibitors
that were already FDA approved for use in humans, albeit for
other indications, i.e. cancers. The drugs dasatinib, saracatinib
and bosutinib all possess a low nanomolar IC50 for Src kinase
(0.8, 2.7 and 1.2 n, respectively) (41–43). These drugs have activ-
ity against the phosphorylation of dystroglycan on Y890 in
mouse myoblasts and in wild-type and dystrophic zebraﬁsh,
and all improved the dystrophic phenotype in sapje ﬁsh (data
not shown). Combinations of multiple kinase inhibitors, or ki-
nase inhibitors with proteasome inhibitors, may lead to greater
efﬁcacy and the possibility of reduced side-effects. However, da-
satinib was clearly the most effective leading to a 40% rescue of
the dystrophic phenotype. While this is a signiﬁcant improve-
ment in dystrophic pathology, one has to question, given the hy-
pothesis, why the extent of recovery is not greater. However,
considering the 100% efﬁcacy of the mouse genetic model in pre-
venting phosphorylation of tyrosine 890, with only a partial
amelioration of the dystrophic phenotype, it is perhaps not so
surprising that the pharmacological treatment in zebraﬁsh did
not result in a full recovery. Moreover, these analyses are based
only on our ability to monitor tyrosine phosphorylation at
Y890, as this is the only tyrosine phosphorylation site that has
so far been identiﬁed unequivocally (14,32), and our assumption
that this phosphorylation event is solely responsible for the
degradation of dystroglycan. In fact, our original analyses of
adhesion-dependent tyrosine phosphorylation of dystroglycan
revealed at least one other phospho-tyrosine containing
spot on two-dimensional gels (14). More recently, it has been
demonstrated that Lassa fever virus infection leads to tyrosine
phosphorylation of dystroglycan, and importantly, although
the level of pTyr was reduced when Y890 was mutated, it was
not abolished, providing convincing further evidence for
the existence of a second tyrosine phosphorylation site (44).
Currently, we do not know which other tyrosine residues are
phosphorylated, what contribution this has to the dystrophic
phenotype, nor what kinase is responsible and hence whether
dasatinib is effective at preventing this phosphorylation is
unknown. With a disease like DMD, however, even small reduc-
tions in symptoms can have big impacts on quality of life. And
while any one therapeutic approach is unlikely to give a 100%
Figure 8. Dasatinib treatment rescues swimming ability in sapje larvae. Using
ViewPoint video tracking and analysis, the overall distance moved by sapje
larvae is signiﬁcantly lower compared with wild-type siblings (A, P < 0.0001).
Each bar represents mean tracking data from 36 larvae from three separate
multiwell plates, and error bars represent SEM. (B) Representative traces for
three sapje (sap, bottom) and three sibling larvae (top), light grey traces
represent periods of fast movement and dark grey periods of slow movement.
(C) Sapje and control larvae were treated with the indicated concentrations of
dasatinib (µM), or DMSO only, from 3 to 5 dpf. Dasatinib has a dose-dependent
effect in increasing swimming duration compared with vehicle-alone up to a
maximum concentration of 1 µ. One micromolar dasatinib had no effect on
swimming activity of wild-type zebraﬁsh. One-way ANOVA analysis of
ViewPoint tracking data indicated a signiﬁcant increase between dasatinib-
treated and control groups for the distance moved (one-way ANOVA: F = 3.188,
df = 2.69, P = 0.0474, followed by Dunnett’s multiple comparison test: *P < 0.05,
ns = non-signiﬁcant).
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recovery, combinations of different therapeutic approaches
aimed at stabilizing the DGC, for example, exon skipping to
partially restore dystrophin expression, combined with tyrosine
kinase inhibitors to reduce degradation of dystroglycan, could
have an increased efﬁcacy.
Materials and Methods
Zebraﬁsh
Heterozygous sapjet222a (6), dag1hu3072 (40) or LWT zebraﬁsh were
maintained as described previously (18). Animal experimenta-
tion was carried out in accordance with UK Home Ofﬁce regula-
tions and was approved by the local ethical committee.
Embryos were collected and raised at 28°C under standard condi-
tions (45). For all experiments, embryos were dechorionated at
24 hpf using 0.1 mg/ml pronase in E3media for 30 min. Dechorio-
nated embryos were then treated for various times with different
concentrations of drugs or vehicle alone, as indicated in the re-
sults section. Drugs or vehicle (DMSO) was added directly to the
E3 medium in multiwell plates at the start of the experiment
and left for the duration without change. For treatments begin-
ning before 3 dpf, embryos were treated in batches of 50 per
well. The percentage of ﬁsh showing a muscle phenotype in
each treatment group was compared with a DMSO-only control
treatment group. DMSO-only treated ﬁsh were expected to
show a muscle birefringence phenotype with Mendelian fre-
quency of 25% sapje ﬁsh per group (actual recorded frequencies
were 22–28%). For sodium dodecyl sulphate–polyacrylamide gel
electrophoresis (SDS–PAGE) anaylsis, sapje–/– ﬁsh were selected
post-treatment by birefringence. For embryos treated between 3
and 5 dpf, homozygote sapje embryos were sorted using birefrin-
gence prior to drug treatment. Embryoswere treated as described
above, but using 10 embryos per well. Phenotypically normal sib-
lings were used as controls. The degree of rescue of the dystroph-
ic phenotype was determined as described previously (18), and
the severity of the muscle phenotype by counting the number
of damaged somites. Fish were categorized as displaying wild-
type, mild, moderate and severe phenotypes, shown in Supple-
mentary Material, Figure S4c. Wild-type is undamaged, whereas
mild, moderate and severe represent disrupted birefringence
across 1–5, 5–10 or 10+ somites, respectively (Supplementary
Material, Fig. S4). There were no survival or toxicity issues with
any of the treatments used in the study. High-speed video-
tracking motion analysis of zebraﬁsh embryos was performed
using a ViewPoint ZebraLab system (ViewPoint, Lyon, France)
and as described in (27). To stimulate swimming activity, ﬁsh
were subjected to four periods of 30 s light followed by 2 min
dark over a 10 min period.
Immunoﬂuorescencemicroscopy was performed on embryos
ﬁxed in 4% PFA at 4°C overnight or 2 h at room temperature. For
labelling of F-actin, ﬁxed embryos were incubated with 1:20
rhodamine phalloidin in phosphate-buffered saline (PBS) con-
taining 0.1% Triton X-100. For antibody staining, ﬁxed embryos
were permeabilized with pre-cooled acetone at −20°C, blocked
in PBS containing 1% bovine serum albumin, 1% DMSO and 1%
Triton X-100, and incubated overnight in blocking solution
containing the appropriate dilution of antibody. Imaging was
carried out on an Olympus ﬂuoview-1000 confocal microscope.
For western blot analysis of zebraﬁsh larvae, whole larvae were
homogenized in RIPA buffer and boiled in SDS sample buffer
before separation by SDS–PAGE and transfer to PVDF. sapje–/–
larvae were identiﬁed by birefringence prior to homogenization
(Figs. 5 and 6).
Myoblasts
H2kb-tsA58myoblast cellsweremaintained and subjected to sur-
face biotinylation pulse-chase assay as described previously (19).
The preparation and use of MultiDsk ubiquitin binding protein
and use to pull-down ubiquitinated proteins has been described
(23). Immunoprecipitation, SDS–PAGE and western blotting (WB)
of β-dystroglycan was carried out as described in reference (46).
Drugs, inhibitors and antibodies
Dasatinib was obtained from Selleckchem (Munich, Germany)
and Pyr-41 and MG132 from Sigma-Aldrich (Gillingham, UK).
The following antibodies were used in WB and/or immunoﬂuor-
escence (IF) applications. Non-phosphorylated β-dystroglycan
[MANDAG2; WB 1:100, IF 1:100 (47)], β-dystroglycan phosphory-
lated at tyrosine 892 [1709; WB 1:500 (13,19)], α-tubulin (WB
1:3500, Sigma-Aldrich), ubiquitin (WB 1:100, Enzo Life Sciences),
biotinylated Concanavalin A (WB 1:4000, Vector Labs), western
blots were detected by species-speciﬁc horseradish peroxidase
conjugated to secondary antibodies or to streptavidin (1:5000,
Sigma-Aldrich) and detected by ECL. In immunoﬂuorescence,
primary antibodies were detected by species-speciﬁc Alexa
Fluor-conjugated secondary antibodies (IF 1:200, Molecular
Probes) and F-actin was detected with rhodamine-conjugated
phalloidin (IF 1:20, Molecular Probes).
Supplementary Material
Supplementary Material is available at HMG online.
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